Psoriasis-Associated Erectile Dysfunction and Metabolic Syndrome Improve With 12-Week Intervention
June 17, 2024 / Metabolic Syndrome / Obesity / Psoriasis Treatment
A 12-week lifestyle modification program improved plaque psoriasis severity, psoriasis-associated erectile dysfunction (ED), and metabolic syndrome (MeTS) in obese men through diet and exercise interventions, demonstrating significant benefits across these conditions.
New study reveals immune system impact in polycystic ovary syndrome
June 17, 2024 / Polycystic Ovary Syndrome / Immune System / Metabolic Dysfunction
A new study reveals that high androgen levels in polycystic ovary syndrome (PCOS) alter immune cells, potentially contributing to reproductive complications and metabolic disorders. These findings highlight immune dysfunction as a novel target for PCOS treatment.
Pre-conceptional paternal diet impacts on offspring testosterone homoeostasis via epigenetic modulation of cyp19a1/aromatase activity
June 17, 2024 / Paternal Diet Impact / Pre-conception Health / Epigenetic Inheritance
Paternal diet before conception impacts offspring’s testosterone regulation and metabolism through epigenetic changes in the cyp19a1/aromatase gene. High-fat diets in fathers can lead to hypoandrogenism and metabolic issues in male offspring, highlighting the significance of pre-conception paternal health.
Aim to lower cardiometabolic disease risk when considering dietary pattern for obesity
June 14, 2024 / Cardiometabolic Disease / Mediterranean Diet / Obesity / Dietary Patterns
Dietary changes, such as adopting a Mediterranean diet and reducing portion sizes, can improve cardiometabolic health in people with obesity. Time-restricted eating shows limited benefits. Physical activity is crucial for enhancing insulin sensitivity and overall health.
GLP-1 Meds May Help Extremely Obese Qualify for Weight-Loss Surgery
June 14, 2024 / GLP-1 / Weight-loss Drug / Obesity
GLP-1 agonist medications can help extremely obese patients lose sufficient weight to qualify for bariatric surgery, with combination drug therapy proving most effective in pre-surgery weight loss.
GLP-1s Reduced Secondary Stroke Risk in Patients With Diabetes, Obesity
June 14, 2024 / GLP-1 RAs / Secondary Stroke Prevention / Diabetes Stroke Risk Reduction / Obesity / GLP-1
GLP-1 receptor agonists (GLP-1 RAs) reduce secondary stroke risk by up to 16% in stroke survivors with diabetes or obesity. This meta-analysis underscores the potential for GLP-1 RAs to be widely implemented by stroke specialists.
Cushing Syndrome Associated With Gut Microbial Dysbiosis and Cortisol-Degrading Bacteria
June 14, 2024 / Cushing Syndrome / Gut Microbiota / Metabolic Disturbances
A study found significant gut microbial dysbiosis in patients with Cushing syndrome (CS), identifying bacteria like Ruminococcus gnavus that degrade cortisol. This dysbiosis may influence steroid hormone levels, contributing to CS pathogenesis and metabolic disturbances.
Pre-operative use of GLP-1s may reduce complications after metabolic, bariatric surgery in patients with extreme obesity
June 13, 2024 / GLP-1 / Obesity / Weight Loss / Metabolic
Pre-operative use of GLP-1 agonists significantly reduces post-operative complications in patients with extreme obesity undergoing metabolic and bariatric surgery, with multimodal therapy showing the greatest weight loss and BMI reduction.
A Common Health Disorder You’ve Probably Never Heard Of
June 13, 2024 / Cardiovascular-kidney-metabolic Syndrome / Type 2 Diabetes / Obesity / Kidney Health
Cardiovascular-kidney-metabolic (CKM) syndrome links heart, kidney, and metabolic health, affecting nearly 90% of U.S. adults. Addressing risk factors like obesity and high blood pressure through lifestyle changes and medications can prevent progression and improve overall health.
Osilodrostat improves comorbid hypertension, diabetes for adults with Cushing’s disease
June 11, 2024 / Cushing’s Disease / Hypertension Diabetes improvement / Cardiometabolic Disorders Management
Long-term osilodrostat therapy significantly improves comorbid hypertension and diabetes in adults with Cushing’s disease, reducing blood pressure and HbA1c levels over 72 weeks. This highlights the potential of osilodrostat in managing cardiometabolic disorders associated with Cushing’s disease.
Artemisinins: A new hope for women with polycystic ovary syndrome
June 13, 2024 / Artemisinins polycystic ovary syndrome / PCOS
Artemisinins, plant-derived compounds known for their antimalarial properties, show promise in treating polycystic ovary syndrome (PCOS) by suppressing ovarian androgen production. A pilot clinical study demonstrated significant improvements in PCOS biomarkers and menstrual regularity without side effects.
Study links antidepressant use and epigenetic aging to higher mortality risk in postmenopausal women
June 13, 2024 / Mortality Risk / Epigenetic aging postmenopausal women / Depressive symptoms mortality / Postmenopausal health risks
Antidepressant use, depressive symptoms, and accelerated epigenetic aging are linked to higher all-cause mortality in postmenopausal women. GrimAge acceleration partially mediates this effect, highlighting the need for further research in diverse populations.
Eating more choline may help lower heart disease risk
June 12, 2024 / Choline Heart Disease Prevention / Cardiovascular Disease / Choline Benefits
Moderate choline intake from whole foods may reduce the risk of atherosclerotic heart disease. Experts advise obtaining choline from a balanced diet rather than supplements, alongside other heart-healthy lifestyle changes.
Gastric bypass maintains weight loss and diabetes remission over 15 years, study shows
June 12, 2024 / Roux-en-Y Gastric Bypass / Weight Loss / Type 2 Diabetes Management
Roux-en-Y gastric bypass surgery maintains significant weight loss and type 2 diabetes remission for up to 15 years, with a 54% diabetes remission rate at three years and 38% at 15 years. The procedure also resulted in stable long-term weight loss.
Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, Diabetes and Rare Diseases by Unlocking the Full Therapeutic Potential of the Small Intestine
June 11, 2024 / Obesity / Synt-101 / Weight loss / Small Intestine Drug Absorption / Oral GLP-1 Alternatives
Syntis Bio launches to develop oral therapies targeting the small intestine for treating obesity, diabetes, and rare diseases. Its lead program, SYNT-101, mimics gastric bypass effects to promote weight loss. Human trials are ongoing, with further pipeline expansion planned.
Metabolic and bariatric surgery found to prevent pre-diabetes from developing into type 2 diabetes in most patients
June 11, 2024 / Metabolic Surgery Diabetes Prevention / Bariatric Surgery / Pre-diabetes / Obesity
Metabolic and bariatric surgery significantly reduces the progression from pre-diabetes to type 2 diabetes in patients with severe obesity, making them 20 times less likely to develop the disease over 15 years compared to those who do not have surgery.
Bariatric surgery better for weight loss than GLP-1 drugs such as Ozempic
June 11, 2024 / Bariatric Surgery / GLP-1 Drug / Obesity Treatment / Weight Loss
Bariatric surgery offers more significant and sustained weight loss than GLP-1 drugs like Ozempic. While GLP-1 medications can help, weight often returns once they are stopped. Surgery remains the most effective long-term obesity treatment.
Abbott receives FDA nod for 2 OTC continuous glucose monitoring systems
June 11, 2024 / Abbott Continuous Glucose Monitors / FDA Approval
Abbott received FDA approval for two over-the-counter continuous glucose monitoring systems, Lingo and Libre Rio. Lingo targets general health improvement, while Libre Rio is for adults with Type 2 diabetes managing through lifestyle changes. Both leverage Abbott’s FreeStyle Libre technology.
Insulin-treated type 2 diabetes patients unwilling to participate in intensive lifestyle intervention, research suggests
June 11, 2024 / Insulin-treated Diabetes Intervention / Type 2 Diabetes
A study found that adults with insulin-treated type 2 diabetes show low willingness to participate in intensive lifestyle interventions (ILI). Only 0.4% of eligible participants expressed interest, citing restrictive diets and demanding intervention as major barriers.